Literature DB >> 24792024

A late presentation of isolated lymph node tuberculosis postintravesical BCG therapy for superficial bladder cancer: a novel case.

Ali Moostapha Tasleem1, Branislav Varga, Wasim Mahmalji, Sanjeev Madaan.   

Abstract

Intravesical BCG immunotherapy is commonly used in the treatment of superficial bladder cancer. We recount the case of an 82-year-old British man who completed a course of BCG immunotherapy in 2011 for superficial bladder cancer, and presented in January 2013 with a loss of appetite, loss of weight and severe back pain. CT scanning, followed by MRI displayed a 5.7 cm × 5 cm conglomerated necrotic, haemorrhagic mass of lymph nodes in the para-aortic region. A CT-guided biopsy revealed granulomatous inflammation, focal fibrosis and acid-fast bacilli consistent with Mycobacterium tuberculosis (TB). The patient was treated with combination antituberculous medication, and is recovering. To our knowledge, this is the only reported case of lymph node TB secondary to intravesical BCG immunotherapy. We suggest that in patients treated with postintravesical BCG with enlarged lymph nodes, a diagnosis of secondary TB should be considered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792024      PMCID: PMC4024575          DOI: 10.1136/bcr-2014-204037

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Caseating granulomas on the glans penis as a complication of bacille calmette-guérin intravesical therapy.

Authors:  C G French; L Hickey; D G Bell
Journal:  Rev Urol       Date:  2001

2.  Mycobacterium bovis vertebral osteomyelitis and discitis with adjacent mycotic abdominal aortic aneurysm caused by intravesical BCG therapy: a case report in an elderly gentleman.

Authors:  Samad Samadian; Frank Murray Phillips; Dhafer Deeab
Journal:  Age Ageing       Date:  2012-11-14       Impact factor: 10.668

3.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

4.  Primary tuberculosis of glans penis after intravesical Bacillus Calmette Guerin immunotherapy.

Authors:  V K Sharma; P K Sethy; P N Dogra; Urvashi Singh; P Das
Journal:  Indian J Dermatol Venereol Leprol       Date:  2011 Jan-Feb       Impact factor: 2.545

Review 5.  Tuberculous abdominal aortic pseudoaneurysm penetrating the left psoas muscle after BCG therapy for bladder cancer.

Authors:  S Wada; Y Watanabe; N Shiono; H Masuhara; S Hamada; T Ozawa; T Fujii; H Yokomuro; M Kawasaki; K Yoshihara; N Koyama
Journal:  Cardiovasc Surg       Date:  2003-06

6.  Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy.

Authors:  Faraz Kureshi; Amer N Kalaaji; Larry Halvorson; Mark R Pittelkow; Mark D P Davis
Journal:  J Am Acad Dermatol       Date:  2006-08       Impact factor: 11.527

7.  Incidental detection of granulomatous prostatitis by F-18 FDG PET/CT in a patient with bladder cancer: a rare complication of BCG instillation therapy.

Authors:  Seyfettin Ilgan; Gokhan Koca; Sadi Gundogdu
Journal:  Clin Nucl Med       Date:  2009-09       Impact factor: 7.794

Review 8.  Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

Authors:  M D Shelley; T J Wilt; J Court; B Coles; H Kynaston; M D Mason
Journal:  BJU Int       Date:  2004-03       Impact factor: 5.588

9.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 10.  Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guérin.

Authors:  Gregory E J Harding; D Kirk Lawlor
Journal:  J Vasc Surg       Date:  2007-07       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.